Ritiometan (rituximab) is a monoclonal antibody used to treat certain types of cancers and autoimmune diseases. It is a chimeric monoclonal antibody, meaning it is composed of parts from two different species of animals. The antibody is used to target a specific antigen, CD20, which is found on the surface of certain B cells. By targeting CD20, Ritiometan is able to interfere with the growth and activity of these cells, leading to a decrease in their numbers. Ritiometan is approved to treat non-Hodgkin's lymphoma, rheumatoid arthritis, and granulomatosis with polyangiitis. It is also used off-label to treat other autoimmune diseases and some types of leukemia.
Ritiometan is an antibacterial medication used in nasal sprays to treat infections of the nose and throat, particularly those caused by bacteria. It is marketed under the trade name Nécyrane in France .
While it is effective against some bacteria, it is not typically a first-line treatment for the common cold, which is usually caused by viruses.